혹시 are aston openai(으)로 찾으셨나요?

블로그

• A phase 1b/2, open-label study of adrixetinib (Q702) in combination with intravenous pembrolizumab orally administrated novel Axl/Mer/CSF1R tyrosine kinase inhibitor for which the primary mechanism of action Methods: QRNT-008 (NCT05438420) is an ongoing Phase 1b/2 multicenter, open-label, dose escalation and blog.naver.com · 2025.06.03